A Study of Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Inadequately Controlled on Inhaled Corticosteroids

• Status: Completed
• Trial end date: 2010-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a randomized, double-blind, placebo-controlled study to evaluate the effects of lebrikizumab in patients with asthma who remain inadequately controlled while on chronic therapy with inhaled corticosteroids (ICS).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Genentech, Inc.
• Treatments: Antibodies, Monoclonal

Criteria

Inclusion Criteria:

• Body weight 40 kg--150 kg

• Chest radiograph with no evidence of clinically significant abnormality

• Uncontrolled asthma

Exclusion Criteria:

• Asthma exacerbation during screening

• Known malignancy

• Known immunodeficiency

• Pre-existing lung disease other than asthma

• Uncontrolled clinically significant medical disease

• Current smoker

• History of substance abuse that may impair or risk the patient's full participation in the study, in the judgment of the investigator

• Prior allergic reaction to a monoclonal antibody

• Patients (men and women) of reproductive potential who are not willing to use contraception

• Pregnancy